Generic Drugs

Generic Imatinib Approved in the US for CML: What does it mean for GIST patients?

On February 1, 2016, the commercial launch of the generic version of imatinib mesylate (Gleevec), for CML (Chronic Myeloid Leukemia) was approved by the FDA after the Novartis patent expiration and will become available for the first time in the United States through Sun Pharmaceuticals.

By |2019-09-23T11:28:24-04:00February 10th, 2016|Drug Treatment, Generics, Gleevec, News, Newsletter|
Go to Top